Brodalumab

證據等級: L5

預測適應症: 10 個

Brodalumab (DB11776): Repurposing Evaluation — No TxGNN Predictions Available

One-Sentence Summary

Brodalumab is a fully human monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), approved in the US and EU for moderate-to-severe plaque psoriasis (brand names: Siliq®, Kyntheum®). The current Evidence Pack contains no TxGNN-predicted new indications for this compound, and several critical data fields — including mechanism of action, package insert warnings, and contraindications — are absent. A full repurposing evaluation cannot be completed until these data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Plaque psoriasis (from domain knowledge; not captured in Evidence Pack)
Predicted New Indication	No predictions generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — TxGNN pipeline not yet executed
Taiwan Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Taiwan Market Information

Brodalumab currently has no registered product authorizations in Taiwan (TFDA). No approved products, dosage forms, or indication texts are on record as of this report's data cutoff (2026-04-20).

For reference, the drug is approved in other jurisdictions:

Region	Brand Name	Holder	Approved Indication
United States	Siliq®	AstraZeneca / Bausch Health	Moderate-to-severe plaque psoriasis
European Union / UK	Kyntheum®	LEO Pharma	Moderate-to-severe plaque psoriasis

Note: The above global market data is drawn from domain knowledge, not from the Evidence Pack. It is provided as background context only.

Safety Considerations

Please refer to the package insert for safety information.

The Evidence Pack records no key warnings, contraindications, or drug–drug interactions for brodalumab. The TFDA package insert query returned a result, but the parsed content was not included in this Evidence Pack version. Before any clinical evaluation proceeds, a complete review of the official prescribing information (particularly the boxed warning for suicidal ideation and behaviour associated with IL-17 pathway inhibitors) is mandatory.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is fundamentally incomplete — no TxGNN candidate indications have been generated, and the two blocking data gaps (TFDA package insert and MOA) remain unresolved. Without a predicted indication there is no repurposing hypothesis to evaluate.

To proceed, the following is needed:

Run TxGNN prediction pipeline for Brodalumab (DB11776) to generate ranked candidate indications
Retrieve MOA from DrugBank API (DB11776) — IL-17RA binding mechanism and downstream signalling pathway
Parse TFDA package insert (query log ID 4 returned a result; content must be extracted) — particularly warnings, contraindications, and special populations
Confirm target disease scope — if a specific repurposing indication is already of interest (e.g., inflammatory bowel disease, axial spondyloarthritis, asthma), specify it so a focused evidence search can be initiated
Re-run evidence collection (clinical trials, literature) once a candidate indication is confirmed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.